Skip to Main Content (Press Enter)

Logo UNINSUBRIA
  • ×
  • Home
  • Corsi
  • Insegnamenti
  • Professioni
  • Persone
  • Pubblicazioni
  • Strutture
  • Terza Missione
  • Attività
  • Competenze

UNI-FIND
Logo UNINSUBRIA

|

UNI-FIND

uninsubria.it
  • ×
  • Home
  • Corsi
  • Insegnamenti
  • Professioni
  • Persone
  • Pubblicazioni
  • Strutture
  • Terza Missione
  • Attività
  • Competenze
  1. Pubblicazioni

Charlson comorbidity index, neutrophil-to-lymphocyte ratio and undertreatment with renin-angiotensin-aldosterone system inhibitors predict in-hospital mortality of hospitalized COVID-19 patients during the omicron dominant period

Articolo
Data di Pubblicazione:
2022
Abstract:
Purpose: To investigate the clinical predictors of in-hospital mortality in hospitalized patients with Coronavirus disease 2019 (COVID-19) infection during the Omicron period.
Methods: All consecutive hospitalized laboratory‐confirmed COVID-19 patients between January and May 2022 were retrospectively analyzed. All patients underwent accurate physical, laboratory, radiographic and echocardiographic examination. Primary endpoint was in-hospital mortality.
Results: 74 consecutive COVID-19 patients (80.0 ± 12.6 yrs, 45.9% males) were included. Patients who died during hospitalization (27%) and those who were discharged alive (73%) were separately analyzed. Compared to patients discharged alive, those who died were significantly older, with higher comorbidity burden and greater prevalence of laboratory, radiographic and echographic signs of pulmonary and systemic congestion. Charlson comorbidity index (CCI) (OR 1.76, 95%CI 1.07-2.92), neutrophil-to-lymphocyte ratio (NLR) (OR 1.24, 95%CI 1.10-1.39) and absence of angiotensin-converting enzyme inhibitors (ACEI)/angiotensin II receptor blockers (ARBs) therapy (OR 0.01, 95%CI 0.00-0.22) independently predicted the primary endpoint. CCI ≥7 and NLR ≥9 were the best cut-off values for predicting mortality. The mortality risk for patients with CCI ≥7, NLR ≥9 and not in ACEI/ARBs therapy was high (86%); for patients with CCI <7, NLR ≥9, with (16.6%) or without (25%) ACEI/ARBs therapy was intermediate; for patients with CCI <7, NLR <9 and in ACEI/ARBs therapy was of 0%.
Conclusions: High comorbidity burden, high levels of NLR and the undertreatment with ACEI/ARBs were the main prognostic indicators of in-hospital mortality. The risk stratification of COVID-19 patients at hospital admission would help the clinicians to take care of the high-risk patients and reduce the mortality.
Tipologia CRIS:
Articolo su Rivista
Keywords:
COVID-19; Charlson comobidity index; angiotensin-converting enzyme inhibitors/angiotensin II receptor blockers; mortality; neutrophil-to-lymphocyte ratio; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Comorbidity; Female; Hospital Mortality; Humans; Lymphocytes; Male; Neutrophils; Retrospective Studies; COVID-19; Renin-Angiotensin System
Elenco autori:
Sonaglioni, Andrea; Lombardo, Michele; Albini, Adriana; Noonan, Douglas M; Re, Margherita; Cassandro, Roberto; Elia, Davide; Caminati, Antonella; Nicolosi, Gian Luigi; Harari, Sergio
Link alla scheda completa:
https://irinsubria.uninsubria.it/handle/11383/2140035
Link al Full Text:
https://irinsubria.uninsubria.it//retrieve/handle/11383/2140035/187265/fimmu-13-958418.pdf
Pubblicato in:
FRONTIERS IN IMMUNOLOGY
Journal
  • Accessibilità
  • Utilizzo dei cookie

Realizzato con VIVO | Designed by Cineca | 26.5.1.0